Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Ciccolini

Showing results (21-30 of 168) with videos related to

Pageof 17
Sort By:
Cancer Chemotherapy and Pharmacology|March 9, 2021
Detecting DPD deficiency: when perfect is the enemy of goodJoseph Ciccolini, Gérard Milano, Henk-Jan Guchelaar
JCO Oncology Practice|December 3, 2024
A Big Problem With a Feasible Solution, Not a Small Problem With a Complex SolutionVimal Scott Kapoor, Joseph Ciccolini, Sunil Kapoor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2013
Gender, cytidine deaminase, and 5-aza/decitabine--letterJoseph Ciccolini, Godefridus J Peters, Elisa Giovannetti
Expert Opinion on Drug Metabolism & Toxicology|February 19, 2015
Pharmacogenetics and breast cancer management: current status and perspectivesJoseph Ciccolini, Raphaelle Fanciullino, Cindy Serdjebi, et al.
Bulletin Du Cancer|March 28, 2003
[Dosage regimen optimization in cancer chemotherapy using a mathematical model]Dominique Barbolosi, Gilles Freyer, Joseph Ciccolini, et al.
Nature Reviews. Clinical Oncology|February 10, 2011
Integrating pharmacogenetics into gemcitabine dosing--time for a change?Joseph Ciccolini, Cédric Mercier, Laetitia Dahan, et al.
ISRN Pharmaceutics|April 5, 2012
Optimizing Druggability through Liposomal Formulations: New Approaches to an Old ConceptDimitrios Bitounis, Raphaelle Fanciullino, Athanassios Iliadis, et al.
Expert Review of Clinical Pharmacology|May 17, 2018
Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticlesAnne Rodallec, Raphaelle Fanciullino, Bruno Lacarelle, et al.
Anticancer Research|July 3, 2019
Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical PharmacologyAnne Rodallec, Raphaelle Fanciullino, Sebastien Benzekry, et al.
Clinical Pharmacology and Therapeutics|June 20, 2020
Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and CombinationsFlorent Ferrer, Raphaelle Fanciullino, Gérard Milano, et al.
Pageof 17

Showing results (21-30 of 168) with videos related to

Sort By:
Pageof 17
Cancer Chemotherapy and Pharmacology|March 9, 2021
Detecting DPD deficiency: when perfect is the enemy of goodJoseph Ciccolini, Gérard Milano, Henk-Jan Guchelaar
JCO Oncology Practice|December 3, 2024
A Big Problem With a Feasible Solution, Not a Small Problem With a Complex SolutionVimal Scott Kapoor, Joseph Ciccolini, Sunil Kapoor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2013
Gender, cytidine deaminase, and 5-aza/decitabine--letterJoseph Ciccolini, Godefridus J Peters, Elisa Giovannetti
Expert Opinion on Drug Metabolism & Toxicology|February 19, 2015
Pharmacogenetics and breast cancer management: current status and perspectivesJoseph Ciccolini, Raphaelle Fanciullino, Cindy Serdjebi, et al.
Bulletin Du Cancer|March 28, 2003
[Dosage regimen optimization in cancer chemotherapy using a mathematical model]Dominique Barbolosi, Gilles Freyer, Joseph Ciccolini, et al.
Nature Reviews. Clinical Oncology|February 10, 2011
Integrating pharmacogenetics into gemcitabine dosing--time for a change?Joseph Ciccolini, Cédric Mercier, Laetitia Dahan, et al.
ISRN Pharmaceutics|April 5, 2012
Optimizing Druggability through Liposomal Formulations: New Approaches to an Old ConceptDimitrios Bitounis, Raphaelle Fanciullino, Athanassios Iliadis, et al.
Expert Review of Clinical Pharmacology|May 17, 2018
Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticlesAnne Rodallec, Raphaelle Fanciullino, Bruno Lacarelle, et al.
Anticancer Research|July 3, 2019
Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical PharmacologyAnne Rodallec, Raphaelle Fanciullino, Sebastien Benzekry, et al.
Clinical Pharmacology and Therapeutics|June 20, 2020
Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and CombinationsFlorent Ferrer, Raphaelle Fanciullino, Gérard Milano, et al.
Pageof 17